Chung et al. investigated 206 cases of NSCLC patients who received EGFR-TKI treatment and found that TAM counts were significantly higher in patients with progressive disease than in those with non-progressive disease. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.